The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.

22 companies currently qualify for inclusion, with 11 filing in U.S dollars and 11 in the Canadian currency. Since our last report, we added three, including Innovative Industrial Properties (NYSE: IIPR) and MariMed (OTC: MRMD), which operate in the U.S., and Cronos Group (TSX: CRON) (NASDAQ: CRON), which is a Canadian licensed producer.

In August, several companies filing in U.S. dollars have reported, including CV Sciences (OTC: CVSI), which saw CBD sales more than triple in its Q2. Terra Tech (OTC: TRTC) saw cannabis sales in California and Nevada grow 19% in its Q2. GrowGeneration (OTC: GRWG), which operates hydroponics stores targeting the industry in multiple states, saw Q2 sales gain 74% despite pressure in its largest market, Colorado. GW Pharma (NASDAQ: GWPH), which recognizes revenue from Sativex outside the U.S., reported FY18-Q3 sales of $3.5 million, a gain of 9%. Innovative Industrial Properties, a REIT with operations across multiple states, experienced growth in revenue of 157% in Q2. Finally, Marimed, which owns and leases facilities and operates a portfolio of brands, saw Q2 sales grow 81%.

Among those companies reporting in U.S. dollars, Green Thumb Industries (CSE: GTII) (OTC: GTBIF), Tilray (NASDAQ: TLRY) and Golden Leaf Holdings (CSE: GLH) (OTC: GLDFF) are all expected to provide quarterly financials during August. Both GTI and Tilray will hold conference calls on the 28th. Tilray has provided guidance that its Q2 sales fell in a range of $8.8-9.2 million.

Of the Canadian companies that report in Canadian dollars, three LPs that trade on the TSX and that qualify for inclusion have reported so far in August. Canopy Growth (TSX: WEED) (NYSE: CGC) beat the consensus estimates marginally, reporting FY19-Q1 sales of C$25.9 million (+63%), with the gains driven by exports to Germany in part. CannTrust (TSX: TRST) (OTC: CNTTF) reported Q2 sales growth of 99%, also slightly ahead of analyst estimates. Cronos Group Q2 sales grew 428%.

Several companies that report in Canadian dollars are expected to file by August 29th, including  MPX Bioceutical  (CSE: MPX) (OTC: MPXEF),  Isodiol International (CSE: ISOL) (OTC: ISOLD) and Sunniva (CSE: SNN) (OTC: SNNVF) are expected to provide quarterly financials by the end of August.  Sentieo reports the analyst consensus for sales at MPX in it FY19-Q1 is C$12.5 million, which would represent annual growth of 145%.

Visit the Public Cannabis Company Revenue Tracker to see the complete list of qualifying companies.

Exclusive article by Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email